Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Takeda Pharmaceuticals will work with Belgium’s TiGenix to develop the latter’s stem cell therapy for Crohn’s disease outside the U.S. TiGenix will receive an up-front payment of $28 million, as well as potential milestone and royalty payments. Takeda also will invest $11 million in the Belgian firm. Separately, Takeda is forming a partnership with Altos Therapeutics to develop Altos’s ATC-1906, an oral dopamine D2/D3 receptor antagonist, for the treatment of gastroparesis. The agreement gives Takeda an exclusive option to acquire Altos through Phase I development of the drug.
This article has been sent to the following recipient: